Dr. Gerstenfeld was nominated for pioneering scientific advancements through cross-disciplinary collaboration and technology, his service on several committees and his mentorship of bone researchers, according to a Jan. 14 news release from the medical school.
He has studied skeletal biology for more than 35 years and has conducted several studies of pharmaceutical compounds for the treatment of fractures and osteoporosis.
His lab was one of the first in the U.S. to develop in-vitro models of bone-forming cells and isolate the proteins and cDNA clones of the cell proteins. It also participated in a NASA study of the effect of weightlessness on bone cells for space shuttle launches in 1994 and 1995.
Dr. Gerstenfeld has served on orthopedic research panels for the National Institutes of Health, NASA and the U.S. Defense Department and participated in special emphasis review panels for the FDA.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
